[Knowledge about metabolic capacity is important in drug therapy]

Area of Science:

• Pharmacogenetics
• Drug Metabolism
• Enzyme Polymorphisms

Context:

• Genetic variations in drug-metabolizing enzymes, like cytochrome P450, are common.
• Individual metabolic capacity varies, leading to classifications of slow or rapid drug metabolism.
• Drug metabolism pathways can be linked to specific enzyme polymorphisms, such as those for debrisoquine and S-mephenytoin.

Purpose:

• To explore the clinical implications of genetic polymorphisms in drug metabolism.
• To highlight how individual metabolic phenotypes influence drug response and concentration.
• To underscore the importance of pharmacogenetic data in drug therapy.

Summary:

• Polymorphisms in drug-metabolizing enzymes create slow and rapid metabolizer phenotypes.
• Drug efficacy and concentration are affected by an individual's metabolic capacity.
• Prescribing certain drugs, like antidepressants and neuroleptics, benefits from knowing a patient's debrisoquine metabolic status.
• Codeine's analgesic effect is absent in slow debrisoquine metabolizers due to impaired conversion to morphine.
• Metabolism of drugs like diazepam, omeprazole, and proguanil is linked to S-mephenytoin oxidation capacity.
• Proguanil's activation, vital for antimalarial effects, is reduced in slow S-mephenytoin metabolizers.

Impact:

• Pharmacogenetic data aids in interpreting therapeutic drug monitoring results.
• Understanding metabolic phenotypes can prevent adverse drug reactions and enhance treatment effectiveness.
• Polymorphic drug elimination is a critical factor in drug assessment and clinical practice.